Biosimilarity Versus Manufacturing Change: Two Distinct Concepts
暂无分享,去创建一个
[1] S. Chow. Assessing biosimilarity and interchangeability of biosimilar products , 2013, Statistics in medicine.
[2] S. Roger,et al. Biosimilars: opportunity or cause for concern? , 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[3] C. Schneider,et al. Toward biosimilar monoclonal antibodies , 2008, Nature Biotechnology.
[4] John R. Engen,et al. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars , 2012, Nature Reviews Drug Discovery.
[6] J. Litten,et al. Comparability and biosimilarity: considerations for the healthcare provider , 2012, Current medical research and opinion.
[7] R. Janknegt,et al. How to select a biosimilar , 2013 .
[8] C. Russell Middaugh,et al. Protein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profiles , 2014, Front. Pharmacol..
[9] M. Wadhwa,et al. Biosimilars: what clinicians should know. , 2012, Blood.
[10] Demonstrating Comparability of Antibody Glycosylation during Biomanufacturing , 2005 .
[11] J. L. Martinez-Hurtado,et al. Biosimilars: Company Strategies to Capture Value from the Biologics Market , 2012, Pharmaceuticals.
[12] Huub Schellekens,et al. Immunogenicity of therapeutic proteins: clinical implications and future prospects. , 2002, Clinical therapeutics.
[13] S. Roger. Biosimilars: how similar or dissimilar are they? , 2006, Nephrology.
[14] Steven Kozlowski,et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. , 2009, Journal of pharmaceutical sciences.
[15] Alain Van Dorsselaer,et al. Characterization of therapeutic antibodies and related products. , 2013, Analytical chemistry.
[16] S. Simoens. Biosimilar medicines and cost-effectiveness , 2011, ClinicoEconomics and outcomes research : CEOR.
[17] Pauline M Rudd,et al. Automated, high-throughput IgG-antibody glycoprofiling platform. , 2013, Analytical chemistry.
[18] A. Link,et al. Identification and quantification of protein posttranslational modifications. , 2009, Methods in enzymology.
[19] S. Lawrence,et al. Public biotech 2013—the numbers , 2014, Nature Biotechnology.
[20] Richard M. Johnson. Guideline on similar biological medicinal products , 2010 .
[21] R Seitz,et al. Taking immunogenicity assessment of therapeutic proteins to the next level. , 2011, Biologicals : journal of the International Association of Biological Standardization.
[22] Marcella Yu,et al. Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans , 2012, mAbs.
[23] V. Quarmby,et al. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities , 2012, mAbs.
[24] Akira Okazaki,et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. , 2007, Glycobiology.
[25] Christine J. Bryson,et al. Immunogenicity of protein therapeutics: The key causes, consequences and challenges. , 2010, Self/nonself.
[26] Gary Walsh,et al. Post-translational modifications in the context of therapeutic proteins , 2006, Nature Biotechnology.
[27] J. Philo,et al. A critical review of methods for size characterization of non-particulate protein aggregates. , 2009, Current pharmaceutical biotechnology.
[29] Robert Fischer,et al. Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity , 2011, Pharmaceutical Research.
[30] S. Roger. Biosimilars: How similar or dissimilar are they? (Review Article) , 2006 .
[31] Huub Schellekens,et al. Biosimilar therapeutics—what do we need to consider? , 2009, NDT plus.
[32] J. Reichert,et al. Approval of the first biosimilar antibodies in Europe , 2013, mAbs.
[33] M. Mccamish,et al. The State of the Art in the Development of Biosimilars , 2012, Clinical pharmacology and therapeutics.